Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

BACKGROUND: Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain–Barré syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Parisi, Alessandro, Fargnoli, Maria Concetta, Cannita, Katia, Irelli, Azzurra, Porzio, Giampiero, Martinazzo, Claudio, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863341/
https://www.ncbi.nlm.nih.gov/pubmed/29707397
http://dx.doi.org/10.1155/2018/2783917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863341/
https://www.ncbi.nlm.nih.gov/pubmed/29707397
http://dx.doi.org/10.1155/2018/2783917

Ejemplares similares